FSGS
First Trust SMID Growth Strength ETF
First Trust SMID Growth Strength ETF seeks to provide investors with long-term capital appreciation by investing primarily in growth-oriented small and mid-cap companies.
US
EQUITY
Rules-Based
MANAGEMENT STYLE
$ 29.5 M
ASSETS UNDER MGMT
60 bp
EXPENSES
Fund Basics
| Inception date | Jun 20, 2017 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | No |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| ELASTIC NV | 1.6 % |
| PTC INC. | 1.5 % |
| VEEVA SYSTEMS INC-CLASS A | 1.5 % |
| ABERCROMBIE & FITCH CO-CL A | 1.5 % |
| HALOZYME THERAPEUTICS INC | 1.4 % |
| DOXIMITY, INC. CLASS A | 1.4 % |
| INSPIRE MEDICAL SYSTEMS, INC. | 1.3 % |
| DOCUSIGN, INC. | 1.3 % |
| HERITAGE INSURANCE HOLDINGS | 1.3 % |
| INTERDIGITAL INC | 1.3 % |
Constituent Breakdown
| Number of holdings | 101 |
| Herfindahl-Hirschman Index | 104 |
| Wgt avg mkt cap (mns) | $10,174 |
| Large cap (>$10bn) | 42.5% |
| Mid cap ($2-10bn) | 47.8% |
| Small cap (<$2bn) | 8.3% |
| Developed mkts. | 99.8% |
| Emerging mkts. | 0.0% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 96.8 % |
 |
JERSEY | 1.1 % |
 |
BERMUDA | 1.0 % |
 |
IRELAND | 1.0 % |
Historical Performance
Standardized Performance (as of 09/30/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 4.3% | 1.7% | 2.5% | 7.5% | 2.3% | -- | -- | 5.2% |
| Dividend Yield | 0.0% | 0.0% | 0.7% | 1.3% | 1.6% | -- | -- | 1.7% |
| Total Returns | 4.4% | 1.7% | 3.2% | 8.8% | 3.9% | -- | -- | 6.9% | Ann. Volatility | 14.7% | 14.8% | 18.4% | 18.8% | 19.9% | -- | -- | 22.5% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.80 | 48% |
| MSCI EAFE | 0.54 | 33% |
| MSCI Emg Mkts | 0.25 | 19% |
Liquidity Measures
| Avg. volume (000) | 1 |
| ADV traded (mns) | $0 |
| Turnover | 0.1% |
| Avg. Bid/Ask (% of price) | 0.48% |
Technical Indicators
| 30d moving avg. (EMA) | $32.77 |
| Relative strength (RSI) | 65 |
| MACD/Signal | 0.58/0.49 |
| Bollinger Bands (Upper/Lower) | $34.59/$31.17 |
| Short interest (% of AUM) | 0.0% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. FSGS |
Expenses vs. FSGS |
ALTAR Score™ vs. FSGS |
|---|---|---|---|---|
| IJK | iShares S&P Mid-Cap 400 Growth ETF | 22.3% | -43 bp | +1.0% |
| MDYG | State Street SPDR S&P 400 Mid Cap Growth ETF | 22.1% | -45 bp | +1.0% |
| IVOG | Vanguard S&P Mid-Cap 400 Growth ETF | 21.1% | -50 bp | +0.9% |
| RFG | Invesco S&P Midcap 400 Pure Growth ETF | 21.1% | -25 bp | +0.2% |
| FSCS | First Trust SMID Capital Strength ETF | 18.1% | 0 bp | +2.4% |
| MCOW | Pacer S&P MidCap 400 Quality FCF Aristocrats ETF | 17.5% | -11 bp | +1.9% |
| BUL | Pacer US Cash Cows Growth ETF | 17.1% | 0 bp | +1.9% |
| GFLW | VictoryShares Free Cash Flow Growth ETF | 16.6% | -21 bp | +0.0% |
| PAMC | Pacer Lunt MidCap Multi-Factor Alternator ETF | 16.2% | 0 bp | +4.8% |
| XMHQ | Invesco S&P MidCap Quality ETF | 15.9% | -35 bp | +1.3% |
Risk and Returns: FSGS vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 10/24/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
4.5%
ALTAR SCORE™
32nd
PERCENTILE
UNDERWEIGHT
ETFRC RATING
There are 1,377 funds in the US Equity category with an average
ALTAR Score™ of 5.5% and a standard deviation
of 2.1%. FSGS's ALTAR Score™ is approximately -0.5 standard
deviations above the category average. This places FSGS in the 32nd percentile
among funds in the category.
Sell-Side Consensus
$40.7
PRICE TARGET
+24.0%
UPSIDE